TY - JOUR AB - The present study evaluated the changes in lipid profile, and the associations between serum protein convertase subtilisin/kexin 9 (PCSK9), microRNA (miR)122 and low‑density lipoprotein variation following treatment of hepatitis C virus (HCV) genotype 1b infection with Daclatasvir/Asunaprevir. A total of 39 patients with HCV genotype 1b infection with chronic hepatitis received a 24‑week treatment regimen of Daclatasvir/Asunaprevir. Laboratory data were obtained for each subject every 4 weeks during treatment and every 12 weeks after treatment. Serum miR122 and PCSK9 were measured at the start of treatment (week 0), end of treatment (week 24), 4 weeks after the end of treatment (week 28), 12 weeks after the end of treatment (week 36) and 28 weeks after the end of treatment (week 52). LDL was increased at week 4 after the start of treatment to week 52. The increased LDL/HDL ratio at week 52 compared with week 4 was also associated with relative miR122 at week 52. At week 4, PCSK9‑active form (A) was lower than that at other time points, and PCSK9‑inactive form (I) exhibited the greatest increase. At week 52, PCSK9‑A was higher than that during treatment, but PCSK9‑I level at week 52 did not markedly differ from that any time point except for week 4. Relative miR122 at week 4 was associated with increased PCSK9‑A at weeks 36 and 52 from the start of DAA. In summary, treatment of HCV with Daclatasvir/Asunaprevir resulted in elevated LDL, and relative miR122 and PCSK9‑A levels in serum appeared to have some association with LDL increase. AD - Department of Gastroenterology, Nagasaki Harbor Medical Center, Nagasaki 850‑8555, Japan Department of Gastroenterology and Hepatology, Graduate School of Biomedical Sciences, Nagasaki University, Nagasaki 852‑8523, Japan Innovation and Translational Research Center, Nagasaki Harbor Medical Center, Nagasaki 850‑8555, Japan Department of Comprehensive Community Care Systems, Graduate School of Biomedical Sciences, Nagasaki University, Nagasaki 852‑8523, Japan AU - Ichikawa,Tatsuki AU - Miyaaki,Hisamitsu AU - Miuma,Satoshi AU - Taura,Naota AU - Motoyoshi,Yasuhide AU - Akahoshi,Hiroshi AU - Nakamura,Junpei AU - Takahashi,Youichi AU - Honda,Tetsurou AU - Yajima,Hiroyuki AU - Uehara,Ryouhei AU - Hino,Naoyuki AU - Narita,Syouhei AU - Tanaka,Hisaya AU - Sasaki,Seina AU - Nakao,Kazuhiko DA - 2019/03/01 DO - 10.3892/br.2019.1189 EP - 164 IS - 3 JO - Biomed Rep KW - hepatitis C virus direct acting anti‑virals low‑density lipoprotein microRNA122 protein convertase subtilisin/kexin 9 PY - 2019 SN - 2049-9434 2049-9442 SP - 156 ST - Changes in serum LDL, PCSK9 and microRNA‑122 in patients with chronic HCV infection receiving Daclatasvir/Asunaprevir T2 - Biomedical Reports TI - Changes in serum LDL, PCSK9 and microRNA‑122 in patients with chronic HCV infection receiving Daclatasvir/Asunaprevir UR - https://doi.org/10.3892/br.2019.1189 VL - 10 ER -